Attomarker, a British company founded in 2008 and spun out from Professor Andrew Shaw’s research at the University of Exeter, specialises in nanophotonic biochemical testing. We’ve received numerous awards and government grants for our innovative contributions to diagnostics.
Our mission is to lead the personalised medicine market by providing rapid, gold-standard tests for timely health decisions. We believe new health challenges demand innovative solutions, enabling clinicians to offer swift, tailored diagnoses and earlier, individualised treatments.
Attomarker’s high-quality tests move beyond traditional labs, making advanced diagnostics accessible in clinics, pharmacies, and at home. Our name, ‘Atto’ (10^-18), reflects our work at the nanoscale. We develop complex, multiplex tests using proprietary gold nanotechnology, aiming to deliver the best answers right at the point-of-care, regardless of molecule or sample size.
Our advanced biomarker technology transforms disease detection and management through:
- Early Detection: Providing quantifiable results in minutes for conditions like cancer, enabling rapid, less invasive treatments.
- Precision and Accuracy: High sensitivity and specificity, validated in leading clinical settings, ensure reliable results and confident clinical decisions.
- Non-invasive and Patient-Friendly: Simple, small blood samples collected with innovative self-sampling kits enhance comfort.
- Broad Application: Versatile CE-marked technology for oncology, cardiology, neurology, and more, suitable for various healthcare settings.
- Cost-effective Solutions: Preventing disease progression and reducing unnecessary treatments lowers healthcare costs.
